Disease · HP_0030016
Dyspareunia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Dyspareunia. Diseases, record HP_0030016. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0030016
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Dyspareunia
- Open Targets ID
- HP_0030016
- Highest stage of its drugs
- Approval, for 3 of its 16 drugs, from DailyMed and TTD
Source Open Targets
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ESTRADIOL | CHEMBL135 | Small molecule | Approval | DailyMed | 8 | 5 | 5 | Drugs and targets |
| OSPEMIFENE | CHEMBL2105395 | Small molecule | Approval | DailyMed and TTD | 5 | 3 | 3 | Drugs and targets |
| ESTROGENS, CONJUGATED | CHEMBL1201649 | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets | |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| PRASTERONE | CHEMBL90593 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LETIBOTULINUMTOXINA | CHEMBL3707322 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| MEGESTROL ACETATE | CHEMBL1201139 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| VEHICLE | CHEMBL2108661 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets41
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ESR1 | Estrogen receptor | 5 | Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor modulator | Approval | https://conductscience.org/library/genes/2099 | Drugs and targets |
| ESR2 | Estrogen receptor | 3 | Estrogen receptor agonist; Estrogen receptor modulator | Approval | https://conductscience.org/library/genes/2100 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 3 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| CACNA1A | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/773 | Drugs and targets |
| CACNA1B | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/774 | Drugs and targets |
| CACNA1C | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1E | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/777 | Drugs and targets |
| CACNA1F | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1G | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/8913 | Drugs and targets |
1 to 10 of 41
See all 41 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00729469 | Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity | Phase 3 | 919 | 2013-06-28 | Atrophy, Vaginal Diseases | OSPEMIFENE | Its record names the disease | ClinicalTrials.gov |
| NCT02253173 | Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women | Phase 3 | 764 | 2017-05-25 | Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01845649 | Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia | Phase 3 | 550 | 2022-05-09 | Vulvovaginal Atrophy | ESTRADIOL, VEHICLE | Its record names the disease | ClinicalTrials.gov |
| NCT01376349 | Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms | Phase 3 | 464 | 2017-08-25 | Breast Cancer, Gynecologic Cancer | PRASTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT01301001 | A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response | Not applicable | 230 | 2017-11-08 | Vulvodynia | GABAPENTIN | Its record names the disease | ClinicalTrials.gov |
| NCT01846442 | Topical DHEA Against Vaginal Atrophy | Phase 3 | 218 | 2017-04-28 | Vaginal Atrophy | PRASTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT03493126 | Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function | Phase 4 | 59 | 2021-12-22 | Vaginal Atrophy | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01539317 | Therapy to Prevent Sexual Pain in Breast Cancer Survivors | Phase 3 | 50 | 2015-08-04 | Vulvodynia, Dyspareunia, Breast Cancer, Menopause | LIDOCAINE | Its record names the disease | ClinicalTrials.gov |
| NCT03240081 | Treating Postmenopausal Dyspareunia Where it Hurts | Phase 4 | 50 | 2021-01-20 | Dyspareunia | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01422408 | Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy | Phase 2 | 34 | 2017-08-09 | Breast Carcinoma | FLUOCINONIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Subjects on Ospemifene 60 mg/Day vs Subjects on Placebo: serious adverse events | 6 of 463 | 7 of 456 | 919 | NCT00729469 | Trial comparisons |
| WC3011 Estradiol Vaginal Cream (3 Times/Week) vs Vehicle (3 Times/Week): deaths from any cause | 0 of 277 | 0 of 271 | 548 | NCT01845649 | Trial comparisons |
| WC3011 Estradiol Vaginal Cream (3 Times/Week) vs Vehicle (3 Times/Week): serious adverse events | 3 of 277 | 1 of 271 | 548 | NCT01845649 | Trial comparisons |
| Gabapentin vs Placebo: deaths from any cause | 0 of 89 | 0 of 89 | 178 | NCT01301001 | Trial comparisons |
| Gabapentin vs Placebo: serious adverse events | 0 of 89 | 1 of 89 | 178 | NCT01301001 | Trial comparisons |
| Estradiol vs Placebo: Adverse Outcomes | 0 of 31 | 1 of 28 | 59 | NCT03493126 | Trial comparisons |
| Estradiol vs Placebo: deaths from any cause | 0 of 31 | 0 of 28 | 59 | NCT03493126 | Trial comparisons |
| Estradiol vs Placebo: serious adverse events | 0 of 31 | 0 of 28 | 59 | NCT03493126 | Trial comparisons |
| Topical Liquid Lidocaine vs Topical Saline: serious adverse events | 0 of 25 | 0 of 25 | 50 | NCT01539317 | Trial comparisons |
| 50mcg Estradiol Cream vs 100mcg Estradiol Cream: deaths from any cause | 0 of 25 | 0 of 25 | 50 | NCT03240081 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials28
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0030016
GET https://conductscience.org/api/diseases/v1/HP_0030016/targets?page=2